new currency update Top Related searches

Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Expert: Central enterprises will continue to recruit in A-shares. On the evening of December 9, Huada Jiutian, a domestic EDA leader, announced that China Electronic Information Industry Group Co., Ltd. will become the actual controller of the company. So far, the number of A-share listed companies "incorporated" by central enterprises reached 10 in 2024. The end of 2024 is an important node for central enterprises to optimize the layout of listed platforms. The Work Plan for Improving the Quality of Listed Companies Controlled by Central Enterprises previously issued by the State-owned Assets Supervision and Administration Commission of the State Council made it clear that the adjustment and revitalization of the listing platform should be basically completed by the end of 2024, and it is supported to revitalize through absorption and merger, asset restructuring and cross-market operation, or to withdraw through free transfer and equity transfer, so as to further focus on the main business and advantageous areas. Looking forward to the next layout rhythm of central enterprises in the capital market, many experts interviewed by reporters believe that the pace of "recruiting" of central enterprises in A shares will continue. In the coming period, the cases of central enterprises strengthening their main business through capital operation and giving play to their strategic support and industrial leading functions will be on the rise. (shanghai securities news)Trump appointed TOM BARRACK as the US ambassador to Turkey.

Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Japanese manufacturers' confidence index turned negative to the central bank's forecast in December. A short-term survey in Reuters, Japan, found that Japanese manufacturers' business confidence deteriorated further in December due to concerns about US protectionist policies. The survey of 505 large Japanese non-financial enterprises showed that manufacturers' confidence index fell from 5 in November to -1 in December, which was the first time since last February, and the number of pessimists exceeded optimists for the first time in 10 months. The loss of business confidence may cast a shadow over the Bank of Japan's forecast. The Bank of Japan had previously predicted that a steady recovery driven by rising wages and consumption would help inflation reach the 2% target in a sustainable way and justify further interest rate hikes. Many manufacturing industries have reported that business confidence has declined. Among electronic machinery manufacturers, steel and non-ferrous metal manufacturers, pessimists far exceed optimists.Jin Guanping, Economic Daily: Implement more active and promising macro policies. The article points out that the Political Bureau of the Communist Party of China (CPC) Central Committee held a meeting on December 9 to analyze and study the economic work in 2025, and put forward "implement more active and promising macro policies" and "strengthen unconventional countercyclical adjustment" in view of the macro policy orientation next year, and clearly implement more active fiscal policies and moderately loose monetary policies. This important deployment has released a clear signal of strengthening macro-control and strong and steady growth. Implementing a "more active" fiscal policy means increasing fiscal countercyclical adjustment and improving the effectiveness of fiscal policy while maintaining policy stability and continuity. "Moderately loose" means that monetary policy will better reflect the supportive stance and orientation, maintain a reasonable and sufficient liquidity, and further reduce the comprehensive financing costs of enterprises and residents.

CF40 Research: Three Channels to Expand Domestic Demand. An article published by Guan Wei of China Financial Forty Forum (CF40) pointed out that the expansion of total demand, whether it is to expand consumption or investment demand, should be implemented on credit growth. When credit goes up, residents, enterprises and governments have more money in their pockets, so do expenditures and incomes, as well as profits and investments. At present, there are three main ways to expand credit: first, fiscal policy is exerted and the government borrows money; Second, the monetary policy will exert its strength and reduce the policy interest rate; The third is to stabilize the real estate market, and there can be no further sharp decline. In terms of finance, maintain the intensity of fiscal expenditure in a broad sense, and moderately increase the fiscal deficit to 4% in 2025. In terms of monetary policy, we should take reducing the real interest rate as an important goal, continue to implement "strong interest rate reduction", and timely reduce the interest rate of structural monetary policy tools below the policy interest rate level. In terms of the property market, it will ease the current cash flow pressure faced by real estate enterprises and promote the real estate to stop falling and stabilize from both ends of supply and demand.Jialiqi: It is planned to distribute a cash dividend of RMB 2.8 yuan every 10 shares. Jialiqi announced that it plans to distribute a cash dividend of RMB 2.8 yuan to all shareholders every 10 shares based on the company's existing total share capital of 82,975,500 shares, with a total cash dividend of RMB 23,233,100, accounting for 29.56% of the company's net profit attributable to shareholders of listed companies in the first three quarters of 2024. No bonus shares will be paid this time, and the capital reserve fund will not be converted into share capital, and the remaining undistributed profits will be carried forward to the next year.Yuanyuan Communication: The plan being evaluated and negotiated between the company and toy manufacturers does not involve ByteDance, and the results of subsequent negotiations are still uncertain.